Literature DB >> 8861930

Neurological and developmental problems in pediatric HIV infection.

M Mintz1.   

Abstract

Human immunodeficiency virus type-1 (HIV-1)-associated neurologic disease, known as "HIV-1-associated progressive encephalopathy" (PE), is a common concomitant in the progression towards AIDS. PE, characterized by a triad of symptoms including impaired brain growth, progressive motor dysfunction, and loss or plateau of developmental milestones, is believed to result from both direct and indirect effects of HIV-1 infection on the central nervous system (CNS). Consequent to the hallmark systemic immune deficiency of HIV infection, the CNS becomes susceptible to opportunistic infections which add further morbidity and mortality, and may contribute either directly or indirectly to neurologic symptoms which can often mimic PE. Static encephalopathies (SE) represent fixed, nonprogressive neurologic or neurodevelopmental deficits in HIV-infected children. SE may or may not be caused by HIV infection but are often associated with such identifiable insults as prematurity, in utero exposure to toxins or infectious agents, or head trauma. Additional neurological manifestations of HIV infection are seizures, cerebrovascular complications (i.e., stroke), myelopathies, neuromuscular syndromes, and CNS complications of opportunistic infections. Neurobehavioral aberrations have also been observed in pediatric HIV infection. In addition to the neuropathogenesis, theories regarding the timing and detection of the neurological problems associated with pediatric HIV infection are discussed along with a presentation of current treatment paradigms and their rationales. The importance of identifying the numerous environmental factors, including nutritional status, that may confound the ability to discriminate between a primary or secondary role of HIV infection in the various neurological problems of HIV infection is discussed.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8861930     DOI: 10.1093/jn/126.suppl_10.2663S

Source DB:  PubMed          Journal:  J Nutr        ISSN: 0022-3166            Impact factor:   4.798


  7 in total

Review 1.  Nevirapine: a review of its use in the prevention and treatment of paediatric HIV infection.

Authors:  A Bardsley-Elliot; C M Perry
Journal:  Paediatr Drugs       Date:  2000 Sep-Oct       Impact factor: 3.022

2.  Evidence for developmental dopaminergic alterations in the human immunodeficiency virus-1 transgenic rat.

Authors:  Katy M Webb; Michael Y Aksenov; Charles F Mactutus; Rosemarie M Booze
Journal:  J Neurovirol       Date:  2010-03       Impact factor: 2.643

3.  Longitudinal Cognitive Outcomes in Children With HIV in Zambia: 2-Year Outcomes From the HIV-Associated Neurocognitive Disorders in Zambia (HANDZ) Study.

Authors:  Gauri Patil; Esau G Mbewe; Pelekelo P Kabundula; Hannah Smith; Sylvia Mwanza-Kabaghe; Alexandra Buda; Heather R Adams; Michael J Potchen; Milimo Mweemba; Brent A Johnson; Giovanni Schifitto; Handy Gelbard; Gretchen L Birbeck; David R Bearden
Journal:  J Acquir Immune Defic Syndr       Date:  2022-10-01       Impact factor: 3.771

4.  Malnutrition associated with increased risk of peripheral neuropathy in Peruvian children with HIV infection.

Authors:  Peggy Martínez Esteban; Ton G Thahn; Julio Flores Bravo; Lenka Kolevic Roca; Nicanor Mori Quispe; Silvia M Montano; Joseph R Zunt
Journal:  J Acquir Immune Defic Syndr       Date:  2009-12       Impact factor: 3.731

Review 5.  Central nervous system manifestations of HIV infection in children.

Authors:  Reena George; Savvas Andronikou; Jaco du Plessis; Anne-Marie du Plessis; Ronald Van Toorn; Arthur Maydell
Journal:  Pediatr Radiol       Date:  2009-03-10

Review 6.  The ART of HIV therapies: dopaminergic deficits and future treatments for HIV pediatric encephalopathy.

Authors:  Katy M Webb; Charles F Mactutus; Rosemarie M Booze
Journal:  Expert Rev Anti Infect Ther       Date:  2009-03       Impact factor: 5.091

7.  Regression of attained milestones in an HIV infected infant.

Authors:  P Madhivanan; S N Mothi; N Kumarasamy; T Yepthomi; J Lambert; S Solomon
Journal:  Indian J Pediatr       Date:  2001-10       Impact factor: 5.319

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.